Alan Lader, PhD

Citius Pharmaceuticals, Inc.

Disclosure(s): Citius Pharmaceuticals, Inc.: Senior Vice-President/employee

Poster(s):

• (P-101) A Phase 3 International, Multi-Center, Randomized, Open-Label, Assessor-Blind Study to Evaluate the Efficacy and Safety of Minocycline/EDTA/Ethanol (Mino-Lok) Therapy (MLT) vs Site-Specific Antimicrobial Lock in Combination with Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infection
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET